Equities
  • Price (USD)436.32
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change--
  • Beta0.9110
Data delayed at least 15 minutes, as of Dec 02 2025 14:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

  • Revenue in EUR (TTM)1.43bn
  • Net income in EUR133.03m
  • Incorporated1984
  • Employees5.62k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VIRP:PAR since
announced
Transaction
value
Norbrook Licences LtdDeal completed16 Dec 202516 Dec 2025Deal completed5.77%133.73m
Data delayed at least 15 minutes, as of Feb 10 2026 15:51 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.